header logo image


Page 11«..10111213..»

Archive for the ‘Nano medicine’ Category

Cape Breton University researchers hope to help water woes – TheChronicleHerald.ca

Wednesday, January 29th, 2020

SYDNEY, N.S.

Work taking place at Cape Breton University could help small communities both locally and globally deal with water contamination issues.

Shine (Xu) Zhang is a CBU chemistry professor and holds the Tier II Canada Research Chair in healthy environments and communities and the industrial research chair in applied nanotechnology. He is working on a project that involves electrochemical water treatment which he believes can offer a green, efficient and cost-effective alternative.

Water pollution, water contamination is a global concern but its also a local problem for Cape Breton and Nova Scotia, Zhang said.

He said he wanted to take on water contamination as a research topic because it is such a big issue.

CBU is a local university, but CBU really wants to contribute to the community, Zhang said. The environment is a big issue. Water contamination is also a global issue, therefore, research here, if we do a good job, can not only help local communities but also help people far away from here.

We want to apply what we learn to solve some real-world problems.

His research program aims at exploiting nanotechnology and nanomaterials for environmental and health applications with a focus on water treatment, cancer diagnostics and treatment with precision nanomedicine. Zhang has published 65 journal articles.

He describes the technology hes developed as being relatively simple, with an electrode acting like a filter. One electrode removed organic material while another electrode removed heavy metals.

Water comes through the filter, dirty water becomes clean, Zhang said.

The technology, I feel is useful because, from a research standpoint, energy consumption is very low, so essentially its quite cost-effective. That is compatible, for example, with solar panel, those kinds of various sustainable power source. It can be a very automatic system, so you dont need a lot of manpower to run it.

A request for proposals for a market research consultant issued by CBU recently closed and Zhangs team is currently reviewing the proposals received. It asked for proposals to outline how the consultant would go about understanding and marketing the technology, from lab to market through the successful negotiation of a licence.

Zhang said they are now evaluating the best way to commercialize the technology.

Were looking for different industry partners so that we can do further development of specific products or applications for this to meet different needs, he said. For example, we work with environmental remediation companies, we work with landfill leachate, we work on pharmaceutical wastewater. We want to find industry partners to work on further development.

Its hoped the consultant that they hire will assist in finding those partners. A prototype has been developed.

The ideal starting industry level would be 3,000 litres a day, were about halfway there already, were at about 1,500 litres a day," said Andrew Carrier, who works closely with Zhang.

Carrier noted the technology also works in flows, so you dont need a large quantity of contaminated water to make use of it, and it doesnt take up much physical space. They want the technology to be accessible to as many people who can make use of it as possible, he added.

Its easy to put into a remote location without having to invest much capital, Carrier said.

Zhang noted the technology also doesnt generate any sort of secondary waste as a result of its water treatment.

Zhangs work has been supported by the Atlantic Canada Opportunities Agency, Innovacorp, Springboard Innovation Mobilization program, Nova Scotia Lands as well as CBU.

RELATED:

Read the rest here:
Cape Breton University researchers hope to help water woes - TheChronicleHerald.ca

Read More...

A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN – Dove Medical Press

Wednesday, January 8th, 2020

Yaser H Gholami, 1 4 Lee Josephson, 3 Eman A Akam, 5 Peter Caravan, 5 Moses Q Wilks, 3 Xiang-Zuo Pan, 3, 6 Richard Maschmeyer, 1 Aleksandra Kolnick, 3, 7 Georges El Fakhri, 3 Marc D Normandin, 3 Zdenka Kuncic, 1, 4, 8Hushan Yuan 3

1The University of Sydney, Faculty of Science, School of Physics, Sydney, NSW, Australia; 2Bill Walsh Translational Cancer Research Laboratory, The Kolling Institute, Northern Sydney Local Health District, Sydney, Australia; 3Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; 4Sydney Vital Translational Cancer Research Centre, St Leonards, NSW, Australia; 5The Institute for Innovation in Imaging and the A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States; 6Bouve College of Health Sciences, CaNCURE Program, Northeastern University, Boston, MA, USA; 7Internal Medicine Residency Program, Lahey Hospital and Medical Center, Burlington, MA, USA; 8The University of Sydney Nano Institute, Sydney, NSW, Australia

Correspondence: Hushan YuanGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 149 13 th Street, Charlestown, MA 02129, USATel +1 617-643-1963Email hyuan@mgh.harvard.edu

Purpose: Using our chelate-free, heat-induced radiolabeling (HIR) method, we show that a wide range of metals, including those with radioactive isotopologues used for diagnostic imaging and radionuclide therapy, bind to the Feraheme (FH) nanoparticle (NP), a drug approved for the treatment of iron anemia.Material and methods: FH NPs were heated (120C) with nonradioactive metals, the resulting metal-FH NPs were characterized by inductively coupled plasma mass spectrometry (ICP-MS), dynamic light scattering (DLS), and r 1 and r 2 relaxivities obtained by nuclear magnetic relaxation spectrometry (NMRS). In addition, the HIR method was performed with [ 90Y]Y 3+, [ 177Lu]Lu 3+, and [ 64Cu]Cu 2+, the latter with an HIR technique optimized for this isotope. Optimization included modifying reaction time, temperature, and vortex technique. Radiochemical yield (RCY) and purity (RCP) were measured using size exclusion chromatography (SEC) and thin-layer chromatography (TLC).Results: With ICP-MS, metals incorporated into FH at high efficiency were bismuth, indium, yttrium, lutetium, samarium, terbium and europium (> 75% @ 120 oC). Incorporation occurred with a small (less than 20%) but statistically significant increases in size and the r 2 relaxivity. An improved HIR technique (faster heating rate and improved vortexing) was developed specifically for copper and used with the HIR technique and [ 64Cu]Cu 2+. Using SEC and TLC analyses with [ 90Y]Y 3+, [ 177Lu]Lu 3+ and [ 64Cu]Cu 2+, RCYs were greater than 85% and RCPs were greater than 95% in all cases.Conclusion: The chelate-free HIR technique for binding metals to FH NPs has been extended to a range of metals with radioisotopes used in therapeutic and diagnostic applications. Cations with f-orbital electrons, more empty d-orbitals, larger radii, and higher positive charges achieved higher values of RCY and RCP in the HIR reaction. The ability to use a simple heating step to bind a wide range of metals to the FH NP, a widely available approved drug, may allow this NP to become a platform for obtaining radiolabeled nanoparticles in many settings.

Keywords: nanomedicine, radiolabeling, radionuclide therapy, HIR, Feraheme

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continued here:
A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN - Dove Medical Press

Read More...

The application of technology in the fields of medicines and living sciences – BPhrm Dv

Wednesday, January 8th, 2020

There are some fascinating possibilities for using nanotechnology in medicine. Some techniques are only imagined, while others are being tested at different stages.

The nanotechnology field of medicine includes applications of currently-developed nanoparticles and longer-range work involving the use of engineered nano-robots to repair cellularly (sometimes called nanomedicine).

Regardless of what you call nanotechnology, it can revolutionize the manner in which we diagnose and treat human corporal and disease damage in the future, and many technologies only imagined a few years ago, are making significant progress towards becoming reality.

A report on the opportunities offered by nanobiotechnology was published by the German pharmaceutical group, VFA.

The report found that Germany holds a strong position with 1,100 companies in space, including nanobiotechnology, the application of technology in the fields of medicines and living sciences, in the area of nanotechnology.

The relatively young research field has the potential to further improve diagnostic and therapeutic chances for diseases which had not or can not have previously been treated sufficiently Currently used in medical and pharmaceutical nanobiotechnological methods include high-data screening to seek new targets structures and substances, alongside the use of nanotechnology

Many nano-cancer therapies as medical devices for the treatment of brain and liver tumors have also been approved since 2010. Many other nano-based life science technologies are currently being developed in different stages.

The VFA supports a rise in nanobiotechnology technical leadership, exploiting the potential of nanomedicine and actively promoting nanomedicine, believing that this is a major advantage for patients.

The still very recent field of research can further enhance the diagnostic and therapeutic prospects for previously incurable or not adequately treatable diseases, explains a concluding statement from the VFAs view of this topic.

Public discussion will continue to highlight the huge opportunities provided by nanobiotechnology and nanobiotechnology applications that patients already can gain from today, the statement says.

The overall aim must be to consider and overcome concerns about this new technology on a large societal basis.

Whatwe'vecaterpillar-trackedand seenwithin thelast four yearsmay be aspiritedscheme,thatwaswithin thepast,terriblye-commerce health-centered totoday,terriblysubtlewith AI drug discovery, clinical trials, and digitalmedicine, etc. In 2018,the wholequantityofcapitalthat wasendowedin the Asia Pacific amounted toconcerning$6.8B.To placein context,within theUSits$8.2B and $2B for Europe,aforesaidJulien de Salaberry, Chiefmilitary officer& Founder,anatomistGrowth Asia

DNA play an important part in humans and their development. DNAs are the core reason behind everything in our life. It shapes our body, functions, features and even the capability of receiving certain diseases. The core of DNAs has not

DNA play an important part in humans and their development. DNAs are the core reason behind everything in our life. It shapes our body, functions, features and even the capability of receiving certain diseases. The core of DNAs has not

Read more:
The application of technology in the fields of medicines and living sciences - BPhrm Dv

Read More...

What are the Upcoming Trends of Nanotechnology in Medicine? – Medical Tech Outlook

Wednesday, January 8th, 2020

Nanotechnology is a rapidly expanding area of research with massive potential in many sectors ranging from healthcare to construction, and electronics.

FREMONT, CA: In the field of medicine, nanotechnology has revolutionized drug delivery, gene therapy, diagnostics, and various other areas of research, development and clinical application. Nanotechnology is a leading technology in medicine, bettering the potential of nanotechnology to target specific cells or tissues is a popular area of interest for the companies producing nanomedicines. Numerous registered clinical trials are in progress and involve nanotechnology; many of these studies are related to oncology and other therapy areas such as autoimmune diseases, anti-fungal agents and rare diseases. Playing a significant role in the transformation of medicine, identifying the trends in nanotechnology industry is essential.

Target Specification

The area of medicinal research involves attaching nanoparticles into drugs or liposomes to enhance specific localization. Different cell types have remarkable properties, and nanotechnology can be used to recognize cells of interest. This method enables associated drugs and therapeutics to reach diseased tissue while bypassing healthy cells.

Controlled Drug Release

The capability to control the discharge of a drug or therapeutic compound from its associated nanotechnology is benefitting a lot of interest from the industry. This triggered release can be gained from inside the body or from outside the body. The internal system consists of changes in the ecosystem of tumours in comparison with the surrounding tissues, while external stimuli comprise temperature change, ultrasound, or light. At present, the research efforts are dedicated to trying to understand how to release diagnostic molecules and drugs from liposomes with heat, and microbubbles using ultrasound.

Understanding Varied Patient Populations

Generally, there is a need for a better understanding of what makes patients distinctive from each other in terms of lack of ubiquitous drug efficacy. This raises a question, why nanotechnologies are not always able to improve the therapeutic output of drugs for an individual patient. Understanding the behaviour of nanomedicines when encountering different physiological characteristics of the patients and their disease states is significant.

Production of Nanomedicine

When compared to standard drug compounds, synthesizing and producing nanomedicine is primarily believed to be more complicated. In a few cases, this can limit the potential of drug manufacturers or pharmaceutical companies to deliver large quantities of nanomedicines. Not addressing the issues related to production may make the companies less interested in investing resources in this industry.

Follow this link:
What are the Upcoming Trends of Nanotechnology in Medicine? - Medical Tech Outlook

Read More...

NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update – Yahoo Finance

Wednesday, January 8th, 2020

Regulatory News:

"After the achievement of major development milestones in 2019, 2020 offers great opportunity for Nanobiotix and NBTXR3 to fulfill unmet patient needs across oncology. Given NBTXR3s universal mode of action, our proof-of-concept in soft tissue sarcoma, and promising results from our phase I trial in head and neck cancers, we are confident that NBTXR3 activated by radiation therapy has the potential to significantly improve treatment outcomes for head and neck cancer patients. Beyond head and neck, we will continue to expand into additional indications and combination therapies. Ultimately, we aim to change the oncology treatment paradigm for millions of patients around the world." Laurent Levy, CEO of Nanobiotix

NANOBIOTIX (Euronext : NANO ISIN : FR0011341205 the Company) today announced its global development strategy for 2020 and beyond, following proof-of-concept (POC) and European market approval for NBTXR3 in locally advanced soft tissue sarcoma of the extremities and trunk wall (Brand Name: Hensify) in 2019. The Company will continue to prioritize its registration pathway in the US and EU for the treatment of head and neck cancers, while also working to advance the Nanobiotix immuno-oncology (I/O) program and evaluate NBTXR3 in other indications such as lung, pancreatic, esophageal, hepatocellular carcinoma (HCC), prostrate, and rectal cancers. To execute this plan, Nanobiotix will focus on H&N cancers while its collaborators (i.e. The University of Texas MD Anderson Cancer Center (MD Anderson) in the US and PharmaEngine in Asia) are working on other indications.

Global Development Plan Visualization

TRIAL

STATUS

ANTICIPATED NEXT STEPS

Development in Head and Neck Moving Forward

Phase III Registration Trial for NBTXR3 in head and neck patients ineligible for cisplatin

TRIAL NAME: STUDY 312

Nanobiotix trial

Design completed based on last interactions with FDA and European payers (EUnetHTA)

Jan 2020 - Submission of final protocol to FDA and other global regulatory bodies

Phase I and Phase I Expansion Trial for NBTXR3 in head and neck patients ineligible for cisplatin or intolerant to cetuximab

TRIAL NAME: Study 102/ 102 Expansion

Nanobiotix trial

Phase I dose escalation completed / data reported 19 patients

Dose Expansion 38 of 44 patients recruited

Q1 2020 - Update of dose escalation patients follow-up

Mid 2020 - First expansion phase data on efficacy and safety of dose expansion

Phase I/II Trial for NBTXR3 combined with cisplatin for head and neck patients

TRIAL NAME: PEP503-HN-1002

PharmaEngine trial

3rd dose level recruiting

H2 2020- Last patient in for 5th (last) dose level

Immuno-Oncology Program with NBTXR3

Phase I Basket Trial for NBTXR3 combined with pembrolizumab or nivolumab in H&N, lung metastasis, liver metastasis patients

TRIAL NAME: Study 1100

Nanobiotix trial

First patients treated

Protocol extended to include patients with lung and liver metastases from any primary tumor. Recruitment ongoing

Mid-year 2020 - first data reported

Phase II Trial of reirradiation with NBTXR3 combined with anti-PD-1/L1 for inoperable, locally advanced HN cancer

Phase II Trial for NBTXR3 combined with anti-PD-1 or anti-PD-L1 in Stage IV lung cancer

Phase I Trial for NBTXR3 combined with anti- CTLA4 and anti-PD-1 or PD-L1 in patients with advanced solid tumors and lung or liver mets

Phase II Trial for NBTXR3 for recurrent/metastatic HNSCC patients with limited PD-L1 expression

MD Anderson trials

Final stage of protocol development

Q2-Q3 2020 - Submission of protocols to FDA

Development Across Other Indications

Phase I Trial for NBTXR3 in hepatocellular carcinoma and liver metastasis patients

TRIAL NAME: Study 103

Nanobiotix trial

Recruitment of the last patient at the 5th (last) dose level (one patient left to be treated)

Q1 2020 - Update on results

Phase I Trial for NBTXR3 in prostate cancer patients

TRIAL NAME: Study 104

Nanobiotix trial

2nd dose level recruiting

Q4 2020 - Update on results

Phase I Trial for NBTXR3 in pancreatic cancer

Phase I Trial for NBTXR3 in lung cancer patients in need of reirradiation

Phase I Trial for NBTXR3 in esophageal cancer patients

MD Anderson trials

Pancreas Regulatory process ongoing

Lung re-irradiation / Esophageal Submission of final protocol to regulatory process

Q2 2020 - First patient treated in pancreas

Q3 2020 - Lung re-irradiation / Esophageal first patient treated

Phase I/II Trial for NBTXR3 combined with chemotherapy in rectal cancer patients

TRIAL NAME: PEP503-RC-1001

PharmaEngine trial

4th (last) dose level recruiting

H2 2020 - Report phase I results

Next Steps in Soft Tissue Sarcoma

Phase III Trial for NBTXR3 in soft tissue sarcoma of the extremities and trunk wall patients

TRIAL NAME: Act.In.Sarc

Nanobiotix trial

Trial completed / data reported

H2 2020- Further follow up of the patients

Post-Approval Trial for NBTXR3 in soft tissue sarcoma of the extremities and trunk wall patients

TRIAL NAME: TBD

Nanobiotix trial

Design established (100 patients)

H2 2020 - Trial authorization by the relevant regulatory bodies expected

Development in Head and Neck Moving Forward

There are approximately 700,000 new head and neck cancer patients worldwide each year300,000 of these patients reside in the US and the European Union (EU) 1. Of these patients at diagnosis, 90% suffer from local disease and the remaining 10% have metastatic disease. 70-80% of all Head and Neck patients will receive radiation therapy, but significant unmet medical needs remain regarding either local control, systemic control, toxicity, or some combination of the three2. This is especially challenging for patients ineligible for platinum-based chemotherapy (cisplatin).

Global Registration Trial for NBTXR3 in Head and Neck Patients Ineligible for Cisplatin

As previously announced, Nanobiotix has begun interacting with the US Food and Drug Administration (FDA) on its regulatory pathway and met with the agency in October 2019 to refine the design elements of Study 312a phase III investigators choice, dual-arm, randomized (1:1) global registration trial including elderly head and neck cancer patients who are ineligible for platinum-based chemotherapy (cisplatin).

More than half of head and neck cancers include large primary tumors which may invade underlying structures and/or spread to regional nodes. Treatment of these locally advanced forms of the disease ordinarily requires aggressive, concerted measures. Due to potential comorbidities and toxicities associated with treatment, elderly and frail patients suffer from limited therapeutic options. Study 312 aims to target the unmet needs of this population.

Patients in the control arm will receive radiation therapy with or without cetuximab (investigators choice), and patients in the treatment arm will receive NBTXR3 activated by radiation therapy with or without cetuximab (investigators choice). The trial will recruit around 500 patients, the initial readout will be based on event-driven progression-free survival (PFS), and the final readout will be based on PFS and overall survival (OS). The study will be powered to demonstrate the OS superiority of NBTXR3 activated by radiation therapy. In addition, quality of life (QoL) will be measured as a key secondary outcome.

The Companys next step is to submit the final trial design to FDA and other global regulatory bodies within the month. A futility analysis is expected 18 months after the first patient is randomized, the interim analysis for PFS superiority is expected at 24-30 months, and final analysis will report on PFS and OS. In the event of favorable data from the initial readout, Nanobiotix plans to apply for conditional registration in the US.

Story continues

Confirming Efficacy with Phase I (Study 102) Expansion

Nanobiotix has already reported promising early signs of efficacy for patients with head and neck cancer through Study 1023 a phase I trial of NBTXR3 nanoparticles activated by intensity-modulated radiation therapy (IMRT) in the treatment of advanced-stage head and neck squamous cell carcinoma (HNSCC). The patient population for Study 102 includes elderly and frail patients who are ineligible for cisplatin or intolerant to cetuximab.

As a result of this report, the Company launched an expansion cohort with 44 additional patients to strengthen preliminary efficacy data. Recruitment for the expansion cohort has reached 38 of 44 patients and the initial readout is expected by mid-2020. Depending on the favorability of the final expansion phase data, the Company may seek to expedite the regulatory process in the EU.

Additional Development in Head and Neck with Collaborators

See more here:
NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update - Yahoo Finance

Read More...

Triple Negative Breast Cancer Treatment Market Is Expected To Expand US$ 720 Mn By 2026 – Instanews247

Wednesday, January 8th, 2020

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer. Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints.

These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to crossUS$ 720 Mn by 2026from an estimated valuation of just underUS$ 505 Mn in 2018. This is indicative of aCAGR of 4.7%during the period2018 to 2026.

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs. Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare.

The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market.

Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy.

Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Company Profiles

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer.

Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

See the rest here:
Triple Negative Breast Cancer Treatment Market Is Expected To Expand US$ 720 Mn By 2026 - Instanews247

Read More...

Growing Demand for Eco-friendly Products to Bolster the Growth of the Healthcare Nanotechnology (Nanomedicine) Market during 2015 2021 – Primo…

Wednesday, January 8th, 2020

The comprehensive report published by Persistence Market Research offers an in-depth intelligence related to the various factors that are likely to impact the demand, revenue generation, and sales of the Healthcare Nanotechnology (Nanomedicine) Market. In addition, the report singles out the different parameters that are expected to influence the overall dynamics of the Healthcare Nanotechnology (Nanomedicine) Market during the forecast period 2015 2021.

As per the findings of the presented study, the Healthcare Nanotechnology (Nanomedicine) Market is poised to surpass the value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% over the assessment period. The report includes a thorough analysis of the upstream raw materials, supply-demand ratio of the Healthcare Nanotechnology (Nanomedicine) in different regions, import-export trends and more to provide readers a fair understanding of the global market scenario.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/6370

The report segregates the Healthcare Nanotechnology (Nanomedicine) Market into different segments to provide a detailed understanding of the various aspects of the market. The competitive analysis of the Healthcare Nanotechnology (Nanomedicine) Market includes valuable insights based on which, market players can formulate impactful growth strategies to enhance their presence in the Healthcare Nanotechnology (Nanomedicine) Market.

Key findings of the report:

The report aims to eliminate the following doubts related to the Healthcare Nanotechnology (Nanomedicine) Market:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/6370

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/6370

Reasons to buy from PMR

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

Persistence Market Research

305 Broadway, 7th Floor

New York City, NY 10007

United States

Ph.no. +1-646-568-7751

Link:
Growing Demand for Eco-friendly Products to Bolster the Growth of the Healthcare Nanotechnology (Nanomedicine) Market during 2015 2021 - Primo...

Read More...

Wadia Hospital For Children Launched A In-House Pulverization Department, First FDA Approved In Maharashtra – Mumbai Live

Wednesday, January 8th, 2020

First-of-its-kind in-house Pulverization Department was established at Bai Jerbai Wadia Hospital for Children which is now open for all needy patients in the city. FDA has given special permission and approval after the request from the Hospital. It was inaugurated by CEO Dr. Minnie Bodhanwala. Other dignitaries who were present on the occasion were Dr. S.S. Prabhu (Medical Director), Dr Suhas Pawar (Medical Superintendent), Dr Amjadkhan Pathan (Head Clinical Pharmacology).

Pulverization is the process of reduction of medicine dose as per the need of patients. It means to grind or crush medicines into fine particles and then dividing them into the required doses as per the requirement of the patient. This technique will be useful for non-coated tablets. In order to help paediatric patients enhance their quality of life, the hospital has come forward with a great move of opening a Pulverization Department at a minimal cost. A special nano weighing scale is used for the process of dose reduction.

Also Read:Childrens Day: Wadia Hospital Introduces India's First Therapy Park For Paediatric Patients In Hospital Premises

Dr Minnie Bodhanwala, Chief Executive Officer of the Wadia Hospitals, said,

Earlier, patients relative had to be in the queue for 2-3days, for getting the pulverized medicine (dose reduction) from outside facilities. Due to the delayed dose of medicine, many patients had prolonged hospitalization just waiting for the pulverized medicine from outside. After looking into this issue, the hospital decided to start the in house Pulverization department.

She added, Now, the FDA has given special permission and approval after the request from the hospital as the paediatric dosage is different from what is recommended to the adults. Usually, the medication dosage is dependent upon the weight of the patient and hence, the paediatric patient has very small dosages requirement. Neonatal patients unit also requires nano doses of medicine which is not available in the market. Therefore, the doctor advises reducing the dose into one- forth or one-eight part which is impossible for parents. However, this dose can be reduced by well-qualified pharmacists who can do the Pulverization in the sterile and aseptic areas. The hospital remains at the forefront of the latest technology and promises to give round-the-clock-care to the patients. We are committed to coming up with more such helpful initiatives for the benefit of the patients in the near future too.

Also Read:Nutrition Rehabilitation Centre Facility Introduced At Bai Jerbai Wadia Hospital For Children (BJWHC)

Read more:
Wadia Hospital For Children Launched A In-House Pulverization Department, First FDA Approved In Maharashtra - Mumbai Live

Read More...

Vaccinations in California Rebound Less Than 5 Years After SB 277 According to New Study – California Globe

Sunday, December 29th, 2019

Less than 5 years after SB 277 was signed into law and removed personal belief vaccination exemptions for children in public schools, the number of vaccinated children in California has skyrocketed.

A recently released study in the the medical journal PLOS Medicine has found that measles, mumps, and rubella vaccines have seen a 3.3% increase in California, a similar declination of exemptions, and no major outbreak of diseases like the measles since the Disneyland case in 2014 the very incident that sparked passage of SB 277.

Vaccination rates have also shot up from 92.8% in 2015 to 95% in 2017.

Child vaccinations also saw the largest climb in high-risk counties, where vaccination rates went up nearly 10%.

This is really good news for California, said Dr. Richard Nguyen, a pediatrician. There had been an uptick of parents refusing to vaccinate their kids for all sorts of reasons, but now its getting back to normal.

Less kids are getting sick, and Ive actually been getting apologies from parents who had formerly cursed me out over having to be forced to vaccinate their kids because they believed the myth that they can cause autism or weaken them in some way. I actually got a voicemail last week from a mother of a child I do checkups on who said she was sorry for not believing me and other doctors after her daughter had a recent measles scare.

Recently passed laws such as the hotly contested SB 276, which cut back on the number of medical exemptions and now allows investigations on doctors who write more than 5 medical exemptions a year, also show that California lawmakers and citizens are gradually moving away from anti-vaccination beliefs.

A large reason for the growth is that its now almost forced, said John Graves, a policy expert in Los Angeles. Parents arent given the choice anymore. The vast majority of parents believe in vaccines and want them for their own children because they dont want an outbreak or to spread debilitating diseases. So parents who want to opt out are ostracized.

From the cases Ive seen, other parents understand if its for a religious purpose or because theres a medical reason like an allergy or something to the vaccine. Theyll just be more careful around the children who dont have vaccines. But nearly all parents cant stand those that dont want to do it for the hell of it, or if theyre misguided.

This is a health and wellness issue, and it always has been. If its not for a legitimate reason, most parents think the person who doesnt vaccinate doesnt love their child. Ive seen a lot of similarities between this and in the 70s and 80s when seat-belt buckling for children became a huge issue, when there were claims that the seat belts hurt their kids more than helped them.

But now were seeing the tide turn with those new studies. It just took a lot of time for some parents to start getting it.

Evan V. Symon is the Senior Editor for the California Globe. Prior to the Globe, he reported for the Pasadena Independent, the Cleveland Plain Dealer, and was head of the Personal Experiences section at Cracked. He can be reached at evan@californiaglobe.com.

Continue reading here:
Vaccinations in California Rebound Less Than 5 Years After SB 277 According to New Study - California Globe

Read More...

Heard on the Street: Nominate your favorite local businesses – Kankakee Daily Journal

Sunday, December 29th, 2019

Honor your favorite local businesses by nominating them in the first-ever Daily Journal Readers Choice Awards.

The public is invited to nominate their favorite local businesses in categories such as children and education, dining, entertainment, health and beauty, home services, places, shopping and vehicle dealer and services.

Once the nomination period ends, the public is again invited to vote for their favorite in each of the categories, Jan. 15 through Jan. 28.

Winners in each category will be announced and featured in the Daily Journal in February.

Olivet Nazarene University recently reimagined and revamped the Department of Computer Science and Emerging Technologies, formerly known as the Department of Computer Science.

Based on the advice of industry leaders, the Council of Software Programmers and the Universitys CSET Advisory Council, the Walker School of Engineering and Technology decided to modify requirements, expand course concentrations and add more certification options.

Changes to the curriculum and degree requirements will go into effect for the fall 2020 semester.

The program changes also will incorporate the universitys cybersecurity lab, housed in Reed Hall of Science.

Olivets department of CSET is an Amazon AWS Academy offering courses in cloud foundations, cloud architecture and cloud development. Students can pursue certifications in CompTIA Network+, CompTIA Security+, CompTIA Server+, CompTIA Linux+, AWS-CDA, AWS-CP, AWS-CSA, EC-CIH and EC-CEH and will become familiar with Python, Java, PHP, C and Assembly languages.

ONU offers three degrees in the department, a bachelor of arts degree in computing technology, a bachelor of science degree in computer science and emerging technologies and a bachelor of science degree in cybersecurity.

OAK Orthopedics, with offices in Bradley, Frankfort, New Lenox and Watseka, now offers diagnostic imaging and minimally invasive surgery using NanoScope by Arthrex.

This surgical technology, nano arthroscopy, an even less invasive form of arthroscopy, uses a small camera to find and repair joint problems.

For decades, arthroscopy has provided patients with a minimally invasive joint repair treatment option. Now, nano arthroscopy offers the next step in efficient and precision care for joint injuries and conditions.

The NanoScope is even smaller and more flexible than traditional arthroscopes, and OAK Orthopedics use it as a diagnostic tool with alternative views and a treatment tool.

This technology is going to optimize what we can do for our patients, said fellowship trained sports medicine surgeon Dr. Michael Corcoran of OAK Orthopedics. From navigating a tight or curved joint area to being able to access areas that are difficult to visualize even with an MRI, the NanoScope allows surgeons to see and treat problems in a more efficient way.

See more here:
Heard on the Street: Nominate your favorite local businesses - Kankakee Daily Journal

Read More...

Canterbury father and son’s invention will revolutionise medical treatment – Stuff.co.nz

Saturday, December 28th, 2019

A typical father and son project might mean restoring a classic car or completing a home renovation, but this Christchurch pair have set their sights a little higher. LEE KENNY reports.

Phil and Anthony Butlerhave utilised cutting-edge technologyused in the hunt for the Higgs Boson to invent the world's first 3-D colour X-ray.

Phil is a professor at University of Canterbury and a Fellow of New Zealand Institute of Physics, while Anthony is a clinical radiologist and a professor at University of Otago.

Together they have created the MARS scanner, which will one day replace many of the functions of the X-ray, positron emission tomography (PET) scans and magnetic resonance imaging (MRI).

ALDEN WILLIAMS/STUFF

Phil and Anthony Butler work on an arm scanner at MARS' Christchurch laboratory.

READ MORE:* What will be the biggest scientific breakthrough of 2020?* Defence Force medic's bleeding edge invention wins Manawat's Innovate 2019* Where did the curiosity go?

The non-invasive technique will enable doctors to see colour images from inside the body, allowing them to make a more accurate diagnosis when treating everything from a broken bone to heart disease.

Phil, 72, first thought about the concept while he was atCERN (European Organization for Nuclear Research) in 2002.

Scientists working on the Large Hadron Collider used high-tech Medipix detectors to track particles and it was theorisedthey could also be used to detect X-ray photons.

Anthony joined CERN in 2005 and it was while the Butlerswere on a family holiday in Croatia that they decided to put the theory to the test.

Supplied

A 3-D image of Phil Butler's wrist taken by the MARS scanner in 2018.

They founded MARS Bioimaging in 2007 and today their 50-strong team consists of physicists, radiologists, mathematicians, biologists, engineers and computer scientists.

The company is part owned by University of Canterbury where it is based and has close ties to Otago Medical School.

Anthony, 44, explains the machine works by shining X-rays through the body and measuring the tissue composition before a computer reconstructs the information into a high-resolution 3-D colour image.

"The underlying process is often called spectral photon counting we measure the X-ray beam one photon at a time, which means we need to have very fast electronics to do this."

He says they have been looking at several medical applications for the scanners, across a range of clinical disciplines.

ALDEN WILLIAMS/STUFF

Professor Phil Butler is the chief executive of MARS Bioimaging but still takes a hands-on role.

"We've been working with orthopedic surgeons looking at fracture healing, cardiologists looking at the causes of heart disease and stroke, cancer specialists looking whether we can look at cell lines and the way they progress and we've looked at infectious diseases.

"That covers a large chunk of medicine and I expect we'll see [the scanners]hit the clinics at different times.

"It's going to be routine within a few years for a lot of point-of-care stuff."

The primary difference between the MARS scanner and other techniques is the level of detailed information it can record.

Anthony says the work is so cutting edge that components had to be built from scratch.

Dean Mouhtaropoulos

The MARS scanner was inspired by technology used at CERN, the World's Largest Particle Physics Laboratory.

"We did computer simulations to work out what we should be doing, then we had to come up with the designs, then manufacture it."

Dipanjan Pan, professor in chemical and biological engineering and radiology at University of Maryland Baltimore County, is an expert in nanomedicine and molecular imaging.

He collaborated with the MARS team for several years and says the3-D scanner has the potential to "dramatically change the ambiguity often found in black and white conventional CT imaging".

"Looking through MARS's proprietary photon counting CT 'magic lenses', you are visualising in colour the future of various biological processes as it merges with the present," he says.

"Their powerful reconstruction technique is astounding."

The technology has a range of uses from security and engineeringto physics and astronomy.

123rf

The traditional 2-D X-ray is good at showing solid objects like bones.

But the Butlers are focused on clinical applications and in July 2018 Phil became the first person to be scanned, with images generated of his wrist and ankle.

The next stage will be clinical trials next year when orthopaedic and rheumatology patients from Christchurch will bescanned.

Phil saysthe breakthrough is comparable to the first X-ray images in 1895 and the first low-resolution Computed Tomography (CT) in 1972.

"It's a major step. We went from 2-D to 3-D, now we're going from black and white to colour.

"The other thing that makes ours different from pretty much any other clinical system is we've got very high-resolution, basically 10 times the resolution of any other comparable technology."

Dr Diana Siew, associate director at MedTech Centre of Research Excellence at Auckland Bioengineering Institute, said the MARS X-ray scanner is a "game changer in medical diagnostics" because "it visualises what is happening in the body in a way that has not been achieved before".

"Different components of the body like fat, calcium, water and disease biomarkers show-up on the X-ray images in different colours, thus allowing a fuller and more accurate picture of a patient's condition," she says.

SUPPLIED

The new MRI scanner at Palmerston North Hospital had to be slotted through a hole in the wall when it was installed in April 2019.

"From a research perspective, this is exciting as it could underpin new understanding of disease onset and progression and be used to determine the efficacy of treatments.

"The MARS technology is a world's first and it is so exciting that it is happening in NZ."

As well as heralding a quantum leap in imaging capability, Anthony says the MARS technology will improve health treatment for Kiwis, as not everywhere has access to PET or MRI scanners.

"About half the people in rural New Zealand don't get appropriate cancer treatment, not because the country can't afford it but because the cancer centres are in large hospitals, the same is true for imaging," he says.

"If you are on the West Coast you cannot get a PET scan, you have to come over to Christchurch.

123RF

MRI scanners can record incredible detail but they are large and not widely available.

"So those access issues, we beat most of them because we use X-rays and they are very easy to have in a local practice, every dentist has got one."

Phil added: "One of the design goals for this system is to make it as easy to operate as a dentist's X-ray".

As well as the high cost of PET and MRI scanners, Anthony says there are other practicalities that make them less accessible.

"MRI requires rooms with big machines, you have to have liquid helium cooling it down, you can't put someone in with a pacemaker, certain vascular clips can't go in there [or] hip replacements," he says.

"With PET you have similar things, you have radioisotopes. In New Zealand we have one cyclotron in Wellington producing radioisotopes and they have to be flown around the country, so if it's a windy day in Wellington, no PET imaging can happen in the country."

Supplied

A 3-D image of Phil Butler's ankle, scanned in 2018.

MARS is operated from a secure area of University of Canterbury and as well as full-time staff, research is carried out by 15 PhD candidates.

Phil is in no doubt that a key component of the project's success is that it's based in Canterbury.

"If you look at the electronics or mechanical engineering skills of Christchurch, we can build anything," he says.

"We've got the skills to do it but the people also know each other, whereas if you go to a big city of several million, they can do it but they can't talk to their allied disciplines.

"That goes back to the farming industries, where people had to build their own machines and those skills of being able to build anything are all part of that."

Anthony agrees.

"If you go to really large research institutes they can be really skilled but they tend to have big silos. In New Zealand we tend not to operate that way.

Don Scott/Stuff

The Butlers, pictured here in 2010, examine coloured Iodine and Barium infused tissue.

"I think we're the sweet-spot in terms of size, where there's enough skill around that there's experts but we're not so big that we can't talk to each other."

Almost 15 years since the father and son team decided to embark on the research, they have made huge advances but there is still work to be done.

"If you look at where we were in 2006 or 2007 we were able to measure four colours but we had to do them one after the other, not simultaneously," Anthony says.

"We scanned the abdomen of a mouse, a pretty small object, and it [took] a day to image it and a month to do all the data reconstruction to get a picture to look at."

Day-to-day, Anthony is the company's chief medical officer and scientific lead.

Phil is the chief executive but, but according to Anthony, he still "does a lot of the technical work".

Working with family members can bring its challenges but Anthony says one of the advantages of partnering with his dad is the "innate trust" they have.

"It's actually a real pleasure," he says.

"I'm quite lucky, I didn't start working with him until I was in my early 30s, which meant I'd done all of my qualifications, established my own life.

"He had done many things himself and been pro-vice chancellor of the university and wanted to get more into practical applications so we founded this project together and that's been really nice.

"You're always going to have problems in any relationship but the fact that it's a family member gives you structure where you can actually work through problems and solve them and know that you're on the same team."

View post:
Canterbury father and son's invention will revolutionise medical treatment - Stuff.co.nz

Read More...

MR Solutions participates in the first nanomedicine joint annual meeting in Dijon – BioSpace

Thursday, December 19th, 2019

UK based MR Solutions presented a simultaneous 7T PET/MRI preclinical imaging system optimized for nanoparticle imaging to the first joint annual congress of the French Nanomedicine Society (SFNano), and the French national Competency Cluster in Nanoscience CNano which was held in Dijon in early December.

Nanoparticles (NPs) have demonstrated great potential in diagnostic medicine particularly as contrast agents using MRI scanners. Iron oxide, gold, and gadolinium NPs have been used in preclinical and clinical studies as contrast enhancing agents.

The participants at the SFNano CNano 2019 joint meeting work in the scientific areas of nanomedicine, nanotechnology and nanoscience. MR Solutions presented the technology in a talk to the scientific community and displayed the PET/MRI system at the accompanying exhibition.

MR Solutions 7T PET/MR preclinical imaging system uses dry magnet, or liquid-helium free technology facilitating a compact system for multi-modality imaging. Researchers are able to combine high resolution MRI data with the high sensitivity of PET data for anatomical and quantitative studies.

Fabrice Chaumard, MR Solutions sales and marketing director commented: We were delighted that there was so much interest from the scientific community in our preclinical PET/MRI systems for nanoparticle imaging. This system provides much better imaging data and at a fraction of the cost of two separate systems.

The PET capability is provided by solid state detectors which are incorporated in the bore of the MRI scanner. The scanner combines the exquisite structural and functional characterisation of tissue provided by MRI with the extreme sensitivity of PET imaging for metabolism and tracking of uniquely labelled cell types or cell receptors. This is particularly useful in oncology, cardiology, and neurology research.

MR Solutions is the worlds leading independent developer and manufacturer of preclinical multi-modality MRI technology and remains the only company to deliver a commercial cryogen-free 3T to 9.4T range of compact MRI scanners. In recognition of the companys innovation and business acumen the company has received three Queens Awards for Enterprise for innovation in 2016 and 2019 and for international trade in 2017.

MR Solutions has over 30 years experience and in excess of 2000 installations across the world. This includes sales of their MRI spectrometers. Its scanners are renowned for their excellence in terms of superior soft tissue contrast and molecular imaging ability.

http://www.mrsolutions.com .

< Ends

Follow this link:
MR Solutions participates in the first nanomedicine joint annual meeting in Dijon - BioSpace

Read More...

Woogs World: Lots to learn from Westporters new book – Westport News

Thursday, December 19th, 2019

Elephants have many more cells than humans. However, they dont get cancer.

Eagles can see eight times the magnification of our own eyes. They also perceive ultraviolet light.

Bacteria defend themselves against viral attacks by cutting their own DNA.

Human beings can learn a lot from other living things as small as microbes, as large as elephants and whales.

And what better way to learn about what we can learn than by reading Michael Hehenbergers new book. The longtime Westport resident has just published Our Animal Connection.

In 339 pages, it explores the many ways we can learn about different species adaptations to extreme conditions, their evolution of special capabilities, and the ways they defend against predators and diseases. By studying the vast variety of life forms on earth particularly the top performers Hehenberger hopes that humans can learn and benefit.

Its a dense book, but the author knows his stuff. Hes spent a lifetime studying scientific questions, then coming up with solutions, and hes done it on both molecular and cosmic scales.

Born in Austria, Hehenberger earned a Ph.D. in quantum chemistry at the esteemed Uppsala University in Sweden. He worked for IBM in Europe, specializing in computational chemistry and biology, structural engineering, campus networks and high-performance computing. He moved in 1993 to their research center in San Jose, Calif.

Throughout his IBM career, Hehenberger led collaborations with academic and industrial life sciences organizations. The partnerships were based on joint desires to extend the frontiers of molecular biology, information-based medicine, bio-pharmaceutical research, unstructured data analytics, genomics and nanomedicine.

Three years later, he came east. IBM has facilities in Armonk, Yorktown Heights, White Plains and Somers, N.Y.. But, like many of the companys employees, he found Fairfield County taxes and housing better than Westchesters. He joined the large IBM contingent living in Westport.

His wife met a Wilton Road neighbor, Arlene Skutch, and took painting classes with her. Hehenberger traveled often, and was less involved in the town.

But when he retired in 2013, he joined the Ys Men. Like many retirees in that organization, he kept working. He formed the HM NanoMed Partnership, which organizes conferences and pursues nonomedical and genomic research topics.

And Hehenberger decided to write a book.

Nanomedicine: Science, Business, and Impact was published two years later. Hehenberger describes nanotechnologys intersection with life sciences and healthcare with depth and breadth.

His audience was politicians and businesspeople, including pharmaceutical and biotech executives. The book good excellent feedback. But his publisher priced it high nearly $100 so sales were limited.

Hehenbergers daughter, who has worked with Johnson & Johnson, McKinsey and Harvard, has diabetes. Insulin was first extracted from pigs and cattle. Hehenberger donated a kidney to his daughter, but knows that additional help in fighting the disease could come from animals.

He planned his next book the one about what we can learn from animals as a collaborative effort with a colleague, Zhi Xia, and his daughter. But she got busy, starting a company for patients with chronic diseases, and raising a child, so only he and Zhi worked together.

Zhi is co-founder of BGI, one of the worlds foremost genome sequencing companies. He has published dozens of academic papers and 14 books. They are professional colleagues and share a love for mountains too. Together, theyve traveled to Tibet and the Mount Everest base camp.

The message of their new book, which just started shipping, is simple, Hehenberger says: We need to respect animals, and all living organisms. We can learn a lot from them.

While the human brain is impressive, he notes enabling us to invent microscopes to study tiny organisms and telescopes to search the universe our visual perception cant compare to birds of prey, or even certain insects.

Although we are proud of our ability to run, jump, swim and climb mountains, our best Olympic performances lag behind potential animal competitors.

Our resistance to diseases and the way we recover from injuries are other areas where human performance is not always iimpressive.

The audience for Our Animal Connection is, the author says, anyone interested in animals, science, evolution and our planet.

Unfortunately, it too is priced high: $75.95 for hardcover and $79.95 for Kindle. Hehenberger worries it wont reach as many readers as hed like (hes working on discounts: email mhehen@gmail.com. Hes also hoping for a paperback edition).

As for his passion for mountains, Hehenberger is in the process of comparing the DNA of legendary climbers, like Tibetans, with those of people who live at lower altitudes. The way that mountain dwellers have evolved to deal with hypoxia may have relevance for COPD and cancer.

Who knows? It may also be the subject of his next book.

Dan Woog is a Westport writer, and his Woog's World appears each Friday. He can be reached at dwoog@optonline.net. His personal blog is danwoog06880.com.

Read this article:
Woogs World: Lots to learn from Westporters new book - Westport News

Read More...

Nanomedicine Market Global Industry to Record Significant Growth in the Near Future 2019-2024 – Market Research Sheets

Thursday, December 19th, 2019

Nanomedicine Market

Global Nanomedicine Market Professional Survey Report 2019 share manufacturing companies, product type, technological progress, geographical regions, and applications 2019-2024. The Nanomedicine report looks thoroughly at company strategies, and marketing, expenditure, company planning, and sales. The outlook of this sector has been examined in conjunction with the many challenges and growth opportunities. The Nanomedicine analysis exhibits a strategic report and providing market intelligence that is accurate, trusted and vital for its merchants or to implicitly any organization.

Major Players in Nanomedicine market are:Company 1Company 2Company 3Company 4Company 5Company 6Company 7Company 8Company 9Company 10

Most important types of Nanomedicine products covered in this report are:Type 1Type 2Type 3Type 4Type 5

Most widely used downstream fields of Nanomedicine market covered in this report are:Application 1Application 2Application 3Application 4Application 5

Overview of the Report:The report begins with a market overview and moves on to cover the growth prospects of the Nanomedicine markets. Global Nanomedicine industry 2019 is a comprehensive, professional report delivering market research data that is relevant for new market entrants or established players. Key strategies of the companies operating in the markets and their impact analysis have been included in the report. Furthermore, a business overview, revenue share, and SWOT analysis of theleading players in the Nanomedicine market are available in the report.

Nanomedicine Market: Regional Analysis Includes:

Target Audience of Nanomedicine Market 2019 Forecast to 2024 Market:

The content of the study subjects, includes a total of 15 chapters:

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

Contact Us:Web:www.qurateresearch.comE-mail:[emailprotected]Ph: US +13393375221, IN +919881074592

This post was originally published on Market Research Sheets

The rest is here:
Nanomedicine Market Global Industry to Record Significant Growth in the Near Future 2019-2024 - Market Research Sheets

Read More...

Immix adds Biotech VC Mesa Verde to Investor Syndicate and Receives IRB Approval to Enroll Patients in Phase 1b/2a Cancer Study in the United States -…

Thursday, December 19th, 2019

LOS ANGELES, Dec. 17, 2019 /PRNewswire/ -- Immix Biopharma, Inc., announced today the first closing of a convertible note financing to support the clinical testing of its lead compound Imx-110 in advanced solid tumors. Mesa Verde managing director, Carey Ng, PhD, MBA, also joined the Board.

Immix CEO, Ilya Rachman, MD, PhD, MBA, shared, "We are thrilled to bring on Mesa Verde and Carey as we continue to build our team with executives and board members with successful experience in guiding early-stage clinical companies through similar phases of rapid growth."

With this additional funding, Immix will begin enrolling patients at US-based sites in its study testing Imx-110 in a Phase 1b/2a trial in advanced solid tumors. Immix received IRB approval to begin dosing patients at Synergy Hematology Oncology with offices in Los Angeles and Encino, CA. Dr. Levon Qasabian, MD will be the principal investigator, who stated that, "We are excited to explore the potential of this promising drug and offer it to patients with advanced tumors and limited treatment options."

Interim readouts from the Phase 1b/2a trial in Australia are 100% clinical benefit rate (akin to disease control rate) for all patients who completed the 5th cohort and at least 2 cycles as scheduled - with the longest duration of response being 8-months of stable disease. No treatment-related serious adverse events have been observed to-date and dose escalation is continuing. For information about participating in this study, please visit clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03382340

Immix is also opening a call for investigator initiated studies where the company will provide its lead compound Imx-110 at no charge.

About Imx-110Imx-110 is a first-in-class combination therapy designed to inhibit cancer resistance and evolvability while inducing apoptosis. Imx-110 contains NF-kB/Stat3/pan-kinase inhibitor curcumin combined with a small amount of doxorubicin encased in a nano-sized delivery system for optimal tumor penetration. The nanoparticle is tunable in that it can be bound to various targeting moieties, allowing it to deliver even more payload to tumors or other cell populations of interest, if needed. Imx-110 showed preclinical efficacy in glioblastoma, multiple myeloma, triple-negative breast, colorectal, ovarian, and pancreatic tumor models with the mechanism of action being a 5x increase in cancer cell apoptosis compared to doxorubicin alone, and a wholesale shift in the tumor microenvironment post administration.

About the CompanyImmix Biopharma, Inc. is a privately-held, biopharmaceutical firm focused on developing safe and effective therapies for cancer patients. The company was founded by Vladimir Torchilin, Ph.D., D.Sc., Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University; physician-scientist and clinical researcher Ilya Rachman, MD, PhD, MBA; and Sean D. Senn, JD, MSc., MBA, a senior biotechnology patent attorney. Immix's founding investor is a family office focused on harnessing scientific advances in order to engineer transformative and effective cancer treatments. For more information visit http://www.immixbio.com.

Media ContactRyan Witt+1 (888) 958-1084info@immixbio.com

View original content:http://www.prnewswire.com/news-releases/immix-adds-biotech-vc-mesa-verde-to-investor-syndicate-and-receives-irb-approval-to-enroll-patients-in-phase-1b2a-cancer-study-in-the-united-states-300975006.html

SOURCE Immix Biopharma, Inc.

More:
Immix adds Biotech VC Mesa Verde to Investor Syndicate and Receives IRB Approval to Enroll Patients in Phase 1b/2a Cancer Study in the United States -...

Read More...

Nanomedicine Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025 – Med News Ledger

Saturday, December 7th, 2019

The Nanomedicine research report is a valuable source of data for business strategists. It provides the Nanomedicine overview with growth analysis and historical and futuristic cost revenue demand and supply data. The research analysis provides an elaborative description of the value chain and distributor analysis.

Request Sample Copy of This Report: @https://99marketresearch.com/global-nanomedicine-market-size-status-and-forecast-2019-2025/102924/#Free-Sample-Report

The Nanomedicine market study provides comprehensive data that enhance the understanding, scope and application of this report.

The report provides a basic overview of the industry including definitions and classifications. The Nanomedicine analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Prominent players of Nanomedicine market:

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc):

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

This report studies the Nanomedicine status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyses the top players in global market, and splits the Nanomedicine By product type and applications/end industries.

Read Detailed Index of full Research Study at @ https://99marketresearch.com/global-nanomedicine-market-size-status-and-forecast-2019-2025/102924/

To comprehend 2018-2026 Nanomedicine dynamics in the world mainly, the worldwide 2018-2026 Nanomedicine is analyzed across major global regions. Nanomedicine Also provides customized specific regional and country-level reports for the following areas.

North America: United States, Canada, and Mexico.

South & Central America: Argentina, Chile, and Brazil.

Middle East & Africa: Saudi Arabia, UAE, etc

The study objectives of this report are:

To study and forecast the market size of Nanomedicine

To analyze the global key players, SWOT analysis, value and global market share for top players.

To define, describe and forecast the market by type, end-use and region.

To analyses and compare the market status and forecast among global major regions.

To analyses the global key regions market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends and factors driving or inhibiting market growth.

TOC-

Check here for the discount@https://99marketresearch.com/global-nanomedicine-market-size-status-and-forecast-2019-2025/102924/#Buying-Enquiry

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@99marketresearch.com), who will ensure that you get a report that suits your needs.

See the article here:
Nanomedicine Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025 - Med News Ledger

Read More...

Global Healthcare Nanotechnology Market 2019 by Company, Regions, Type and Application, Forecast to 2025 – Breaking News Updates

Saturday, December 7th, 2019

The research report Healthcare Nanotechnology Market Global Industry Analysis 2019 2025 offers precise analytical information about the Healthcare Nanotechnology market. The report identifies top players in the global market and divides the market into several parameters such as major drivers market strategies and imposing growth of the key players. Worldwide Healthcare Nanotechnology Industry also offers a granular study of the market dynamics, segmentation, revenue, share forecasts and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Healthcare Nanotechnology industry.

This Healthcare Nanotechnology market report bestows with the plentiful insights and business solutions that will support our clients to stay ahead of the competition. This market report contains categorization by companies, region, type, and application/end-use industry. The competitive analysis covered here also puts light on the various strategies used by major players of the market which range from new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and many others that leads to increase their footprints in this market. The transparent research method carried out with the right tools and methods makes this Healthcare Nanotechnology market research report top-notch.

Interesting? Apply for a sample report: http://www.marketresearchstore.com/report/global-healthcare-nanotechnology-market-2019-by-company-regions-491317#RequestSample

Competitive Landscape

Global Healthcare Nanotechnology market is highly split and the major players have used numerous tactics such as new product launches, acquisitions, innovation in products, expansions, agreements, joint ventures, partnerships, and others to increase their footprints in this market.

Key players profiled in the report include: Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith & Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International

Market Segmentation

Healthcare Nanotechnology Market report segmentation on Major Product Type:Nanomedicine, Nano Medical Devices, Nano Diagnosis, Other

Market by Application: Here, various application segments of the global Healthcare Nanotechnology market are taken into account for the research study.

Anticancer, CNS Product, Anti-infective, Other

Enquire Here For Queries Or Report Customization: http://www.marketresearchstore.com/report/global-healthcare-nanotechnology-market-2019-by-company-regions-491317#InquiryForBuying

Regional Analysis

The Healthcare Nanotechnology market report keenly emphasizes on industrial affairs and developments, approaching policy alterations and opportunities within the market. The regional development methods and its predictions are explained in every key point that specifies the general performance and issues in key regions such as North America, Europe, Asia Pacific, Middle East, South America, and Middle East & Africa (MEA). Various aspects such as production capability, demand, product value, material parameters and specifications, distribution chain and provision, profit and loss, are explained comprehensively in the market report.

Key Questions Answered in Global Healthcare Nanotechnology Market Report:-

What will the market growth rate, overview, and analysis by type of global Healthcare Nanotechnology Market in 2026?

What are the key factors driving, analysis by applications and countries Global Healthcare Nanotechnology Market?

What are dynamics, this summary includes analysis of the scope and price analysis of top players profiles of Global Healthcare Nanotechnology Market?

Who are the opportunities, risk and driving forces of the global Healthcare Nanotechnology Market?

Who are the opportunities and threats faced by the vendors in the Global Healthcare Nanotechnology Market?

What are the Global Healthcare Nanotechnology market opportunities, market risk and market overview of the Market?

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia. Also, If you have any special requirements, please let us know and we will offer you the report as you want.

Sorry! The Author has not filled his profile.

Read more:
Global Healthcare Nanotechnology Market 2019 by Company, Regions, Type and Application, Forecast to 2025 - Breaking News Updates

Read More...

Nanotoxicity Studies May Be Affected by Nanoparticles in Syringes – The National Law Review

Thursday, December 5th, 2019

Since 1996, Carla Hutton has monitored, researched, and written about regulatory and legislative issues that may potentially affect Bergeson & Campbell, P.C. (B&C) clients. She is responsible for creating a number of monthly and quarterly regulatory updates for B&C's clients, as well as other documents, such as chemical-specific global assessments of regulatory developments and trends. She authors memoranda for B&C clients on regulatory and legislative developments, providing information that is focused, timely and applicable to client initiatives. These tasks have proven invaluable to many clients, keeping them aware and abreast of developing issues so that they can respond in kind and prepare for the future of their business.

Ms. Hutton brings a wealth of experience and judgment to her work in federal, state, and international chemical regulatory and legislative issues, including green chemistry, nanotechnology, the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), the Toxic Substances Control Act (TSCA), Proposition 65, and the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) program.

Visit link:
Nanotoxicity Studies May Be Affected by Nanoparticles in Syringes - The National Law Review

Read More...

Global Nanobots Market Size by forecasting the high Growth Segments 2019-2025: Xidex Corp, Zymergen Inc, Synthace Limited, Ginkgo Bioworks, Advanced…

Thursday, December 5th, 2019

A recent market study published by QY Research consists of a detailed assessment of the key market dynamics. The report provides the historical as well as present growth parameters of the global Nanobots market. The report features salient and unique factors, which are expected to significantly impact the growth of the global Nanobots market throughout the forecast period.

Scope of the report:

The report commences with a scope of the global Nanobots market that includes the key findings and vital statistics of the market. This market research report also consists of the market value of the major segments of the global Nanobots market. QY Research has found a detailed taxonomy and the definition of the global market that helps the readers to better understand the basic information of the Nanobots market. It also highlights the exclusions and inclusions that help the client to understand the scope of the Nanobots market.

The report consists of key market trends, which are likely to impact the growth of the market over the forecast period. Evaluation of in-depth industry trends is included in the report, along with their product innovations and key market growth.

QY Research report also includes the macro-economic factors, which are likely to influence the growth of the global Nanobots market during the forecast period. Along with the factors, the report also analyzes the growth opportunities of the global Nanobots market. It sheds light on the trends, restraints, and drivers to understand the growth prospects followed by the key players in the global Nanobots market.

Request For Sample of the Report:https://www.qyresearch.com/sample-form/form/894557/global-nanobots-industry-research-report-growth-trends-and-competitive-analysis-2018-2025

Competitive Landscape:

The report provides a list of all the key players in the Nanobots market along with a detailed analysis of the strategies, which the companies are adopting. The strategies mainly include new product development, research, and development, and also provides revenue shares, company overview, and recent company developments to remain competitive in the market.

The Nanobots key manufacturers in this market include:

Xidex CorpZymergen IncSynthace LimitedGinkgo BioworksAdvanced Diamond TechnologiesAdvanced Nano Products Co Limited

Segment Analysis:

The report provides detailed segments based on product type and applications so that the readers can better understand each segment that influences the Nanobots market growth.

By the product type, the market is primarily split into

Microbivore NanorobotsRespirocyte NanorobotsClottocyte NanorobotsCellular Repair Nanorobots

By the end users/application, this report covers the following segments

Nano MedicineBiomedicalMechanicalOther applications

Request For Customization of the Report:https://www.qyresearch.com/customize-request/form/894557/global-nanobots-industry-research-report-growth-trends-and-competitive-analysis-2018-2025

Geographical Outlook:

In 2018, the global Nanobots market size was increased to xx million US$ from xx million US$ in 2014, and it will reach xx million US$ in 2025, growing at CAGR of xx%% between 2019 and 2025.

QY Research report provides a detailed information to the clients about the various factors that are impacting on the growth of the regions across North America (United States, Canada and Mexico), Asia Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines and Vietnam), Middle East and Africa (Turkey, GCC Countries, Egypt and South Africa), and South America (Brazil and others).

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read More Reports:

http://www.marketwatch.com/story/trending-newscontinous-extrusion-machine-market-status-and-prospect-2019-2025-2019-11-26

Read More Reports:

https://www.openpr.com/news/1853458/global-food-manufacturing-and-processing-machinery-market-size

“Global Non-woven Table Linen Market Size Growth, Development and Opportunities in 2019-2025: Intexcomfort , Mungo , Jomar, Inc. , Linomeda etc.”

View original post here:
Global Nanobots Market Size by forecasting the high Growth Segments 2019-2025: Xidex Corp, Zymergen Inc, Synthace Limited, Ginkgo Bioworks, Advanced...

Read More...

Nanobiotechnologies Applications, Markets & Companies Analysis 2019 – Updated Forecasts to 2023 & 2028 – ResearchAndMarkets.com – Business…

Thursday, December 5th, 2019

DUBLIN--(BUSINESS WIRE)--The "Nanobiotechnologies - Applications, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Nanotechnology is the creation and utilization of materials, devices, and systems through the control of matter on the nanometer-length scale (a nanometer is one billionth of a meter. Nanobiotechnology, an integration of physical sciences, molecular engineering, biology, chemistry and biotechnology holds considerable promise of advances in pharmaceuticals and healthcare.

The report starts with an introduction to various techniques and materials that are relevant to nanobiotechnology. It includes some of the physical forms of energy such as nanolasers. Some of the technologies are scaling down such as microfluidics to nanofluidic biochips and others are constructions from bottom up. Application in life sciences research, particularly at the cell level sets the stage for role of nanobiotechnology in healthcare in subsequent chapters.

Some of the earliest applications are in molecular diagnostics. Nanoparticles, particularly quantum dots, are playing important roles. In-vitro diagnostics, does not have any of the safety concerns associated with the fate of nanoparticles introduced into the human body. Numerous nanodevices and nanosystems for sequencing single molecules of DNA are feasible. Various nanodiagnostics that has been reviewed will improve the sensitivity and extend the present limits of molecular diagnostics.

An increase in the use of nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology will be applied at all stages of drug development - from formulations for optimal delivery to diagnostic applications in clinical trials. Many of the assays based on nanobiotechnology will enable high-throughput screening.

Some of the nanostructures such as fullerenes are themselves drug candidates as they allow precise grafting of active chemical groups in three-dimensional orientations. The most important pharmaceutical applications are in drug delivery. Apart from offering a solution to solubility problems, nanobiotechnology provides and intracellular delivery possibilities. Skin penetration is improved in transdermal drug delivery. A particularly effective application is as nonviral gene therapy vectors. Nanotechnology has the potential to provide controlled release devices with autonomous operation guided by the needs.

Nanomedicine is now within the realm of reality starting with nanodiagnostics and drug delivery facilitated by nanobiotechnology. Miniature devices such as nanorobots could carry out integrated diagnosis and therapy by refined and minimally invasive procedures, nanosurgery, as an alternative to crude surgery. Applications of nanobiotechnology are described according to various therapeutic systems.

Nanotechnology will markedly improve the implants and tissue engineering approaches as well. Of the over 1,000 clinical trials of nanomedicines, approximately 100 are selected and tabulated in major therapeutic areas. Other applications such as for management of biological warfare injuries and poisoning are included. Contribution of nanobiotechnology to nutrition and public health such as supply of purified water are also included.

There is some concern about the safety of nanoparticles introduced in the human body and released into the environment. Research is underway to address these issues. As yet there are no FDA directives to regulate nanobiotechnology but as products are ready to enter market, these are expected to be in place.

Future nanobiotechnology markets are calculated on the basis of the background markets in the areas of application and the share of this market by new technologies and state of development at any given year in the future. This is based on a comprehensive and thorough review of the current status of nanobiotechnology, research work in progress and anticipated progress.

There is definite indication of large growth of the market but it will be uneven and cannot be plotted as a steady growth curve. Marketing estimates are given according to areas of application, technologies and geographical distribution starting with 2018. The largest expansion is expected between the years 2023 and 2028.

Profiles of 252 companies, out of over 500 involved in this area, are included in the last chapter along with their 185 collaborations. The report is supplemented with 51 Tables, 32 figures and 800 references to the literature.

For more information about this report visit https://www.researchandmarkets.com/r/lrcr1q

Read more here:
Nanobiotechnologies Applications, Markets & Companies Analysis 2019 - Updated Forecasts to 2023 & 2028 - ResearchAndMarkets.com - Business...

Read More...

Page 11«..10111213..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick